23andMe Holding Co. (ME)

2.2300 +0.0400 (+1.83%) At close: 04:00PM EDT

23andMe Holding Co.

349 Oyster Point Boulevard
South San Francisco, CA 94080
United States
650 938 6300
https://www.23andme.com

Sector(s): Healthcare
Industry: Diagnostics & Research
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Anne Wojcicki	Co-Founder, CEO, Pres & Director	59.28k	N/A	N/A
Ms. Kathy L. Hibbs Esq., J.D.	Chief Admin. Officer and Sec.	567.2k	340.28k	1964
Dr. Kenneth J. Hillan Ch.B., M.B.	Chief Therapeutics Officer	582.2k	N/A	1961
Mr. Joseph Selsavage	Interim CFO & Accounting Officer	N/A	N/A	1963
Dr. Joseph R. Arron M.D., Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Dr. Wade Walke	VP of Investor Relations	N/A	N/A	1966
Ms. Jacquie Cooke Haggarty J.D.	Gen. Counsel & Privacy Officer	N/A	N/A	N/A
Ms. Katie Watson	VP of Communications	N/A	N/A	1978
Mr. Jonathan Ward	Chief Marketing Officer	N/A	N/A	N/A
Ms. Savita Pillai	VP of People	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Corporate governance

23andMe Holding Co.’s ISS governance QualityScore as of 1 February 2023 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder rights: 10; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.